Pricing Log in Create free account

ImmuCell Corporation (ICCC) vs LENZ Therapeutics, Inc. (LENZ)

ImmuCell Corporation and LENZ Therapeutics, Inc. are both Biotechnology companies. ImmuCell Corporation and LENZ Therapeutics, Inc. are of similar size ($94.6M and $90.4M). LENZ Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation has the higher net margin (2.57% vs −1,135.0%) and the higher return on invested capital (7.84% vs 0.00%). Across the 17 metrics below, ImmuCell Corporation leads on 11 and LENZ Therapeutics, Inc. on 6.

Valuation

Metric ICCC LENZ Biotechnology median
P/E 117.02 n/m 10.60
P/S 2.93 8.82 9.40
P/B 2.86 0.57 2.13
Price to free cash flow 21.21 n/m 25.18
EV/EBITDA 14.18 0.58 0.66
EV/Sales 2.91 (6.96) 9.02
Earnings yield 0.85% (129.27%) (32.88%)
Free cash flow yield 4.72% (117.13%) (23.13%)

Profitability

Metric ICCC LENZ Biotechnology median
Gross margin 40.32% 85.35% 68.51%
Operating margin 12.60% (1,211.17%) 0.00%
Net margin 2.57% (1,134.97%) 0.00%
Free cash flow margin 13.79% (1,033.28%) 0.00%
Return on equity 2.57% (72.69%) (51.96%)
Return on assets 1.69% (66.72%) (46.06%)
Return on invested capital 7.84% 0.00% 0.00%

Growth

Metric ICCC LENZ Biotechnology median
Revenue growth (TTM) 8.49% — 6.76%
EPS growth (last fiscal year) 53.85% (21.79%) 29.88%
Revenue growth, 5-year CAGR 12.50% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC LENZ Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 11.66 4.97
Net debt to EBITDA 1.19 3.22 1.01

Dividend

Metric ICCC LENZ Biotechnology median
Dividend yield — 0.00% 0.41%
Payout ratio — — —

Size

Metric ICCC LENZ Biotechnology median
Market cap 90.37m 94.58m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack